Eli Lilly stock up premarket as company’s Q1 revenue beats and it raises guidance

Eli Lilly & Co. shares LLY rose 2% premarket Thursday, after the company posted first-quarter earnings showing a revenue beat and raised its full-year guidance. The company posted net income of $1.345 billion, or $1.49 a share, for the quarter, down from $1.903 billion, or $2.10 a share, in the year-earlier period. Adjusted per-share earnings came to $1.62, below the $1.73 FactSet consensus. Revenue fell 11% to $6.960 billion from $7.810 billion, but was ahead of the $6.

10 a share, in the year-earlier period. Adjusted per-share earnings came to $1.62, below the $1.73 FactSet consensus. Revenue fell 11% to $6.960 billion from $7.810 billion, but was ahead of the $6.864 billion FactSet consensus. The revenue decline was driven by lower volumes as demand for its COVID antibody treatment waned. Excluding that treatment, revenue rose 10%. R&D costs rose 23% to $1.99 billion, mostly due to higher development costs for late-stage assets.

España Últimas Noticias, España Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

Popular diabetes drug Mounjaro could be FDA-approved for weight loss this year, company saysA popular drug currently approved to treat Type 2 diabetes could soon also be approved for weight loss.
Fuente: ABC - 🏆 471. / 51 Leer más »